How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,945 results for

Prostate Cancer Staging

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

11921. Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base. Full Text available with Trip Pro

Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base. Based on the 1998 Patient Care Evaluation (PCE) from the American College of Surgeons National Cancer Data Base (NCDB), the authors described contemporary nationwide patterns of prostate carcinoma presentation, diagnosis, and staging.The authors reviewed 54,212 cases from the 1998 PCE. Demographics, presenting signs and symptoms, tumor characteristics, prostate biopsy techniques, and use (...) ) for metastatic disease (P < 0.005).Most newly diagnosed patients with prostate carcinoma are asymptomatic and have moderately differentiated and organ-confined disease. Compared with symptomatic patients, tumors in asymptomatic men are associated with lower pretreatment PSA levels, AJCC stage, and tumor grade. Selective use of staging evaluations, based on risk of metastatic disease, may be relatively uncommon. The NCDB remains a unique and rich source of novel patient care information and serves

2003 Cancer

11922. Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

growth. Giving paclitaxel together with bortezomib may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of paclitaxel and bortezomib in treating patients with metastatic or unresectable malignant solid tumors. Condition or disease Intervention/treatment Phase Breast Cancer Colorectal Cancer Head and Neck Cancer Lung Cancer Melanoma (Skin) Ovarian Cancer Pancreatic Cancer Prostate Cancer Unspecified Adult Solid Tumor, Protocol Specific Drug: bortezomib Drug (...) Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically confirmed malignant solid tumor that involves an activated Ras/Raf/MAPK pathway, including the following: Breast cancer Prostate cancer Colon cancer Pancreatic cancer Ovarian cancer Non-small cell lung cancer Melanoma Papillary thyroid cancer Metastatic or unresectable disease Standard curative or palliative measures do not exist or are no longer effective No newly diagnosed, untreated, or uncontrolled brain metastases PATIENT

2008 Clinical Trials

11923. Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma

of MEDI-522) in a research protocol in which an investigational agent may be administered Received an investigational agent within 4 weeks prior to study entry Known brain metastases or primary brain tumors History of prior malignancies within the past 5 years other than non-melanomatous skin cancers that have been controlled, carcinoma in situ of the cervix, T1a or T1b prostate cancer noted incidentally during a transurethral resection of the prostate (TURP) with prostate-specific antigen (PSA (...) Posted : May 25, 2005 Last Update Posted : March 14, 2012 Sponsor: MedImmune LLC Information provided by: MedImmune LLC Study Details Study Description Go to Brief Summary: To describe the tumor tissue saturation by MEDI-522 in patients with advanced malignant melanoma. Condition or disease Intervention/treatment Phase Malignant Melanoma Biological: MEDI-522 Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 18 participants

2005 Clinical Trials

11924. Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies

for the treatment of solid tumors. Condition or disease Intervention/treatment Phase Tumor Drug: AV-412 Phase 1 Detailed Description: Although progress has been made, patients with malignancies often either progress after the traditional approach of chemotherapy, surgery, or radiotherapy, or are not candidates for these approaches because of the advances stage of disease. Novel therapies that may offer greater potential than those currently available are urgently needed. AV 412 is a potent inhibitor of human (...) women Primary CNS malignancies; active CNS metastases Hematologic malignancies (includes: leukemia, any form; lymphoma; and multiple myeloma) Active second malignancy or history of another malignancy within 2 years with the exception of: Treated, non-melanoma skin cancers Treated CIS of the breast or cervix Controlled, superficial bladder carcinoma T1a or b prostate carcinoma involving < 5% of resected tissue and PSA within normal limits (WNL) Any of the following hematologic abnormalities

2006 Clinical Trials

11925. Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies

method of contraception during the study and six months following termination of treatment. (Not applicable to patients with bilateral oophorectomy and/or hysterectomy or to female patients who are older than 50 years and have not had a menstrual cycle in more than one year. Patients must have measurable or evaluable disease by staging studies performed within 4 weeks of enrollment (evaluable disease refers to ovarian cancer with an elevated CA-125 or prostate cancer with elevated PSA only) Once MTD (...) Center and Research Institute ClinicalTrials.gov Identifier: Other Study ID Numbers: MCC-13693 USFIRB#101881 First Posted: October 31, 2005 Last Update Posted: February 23, 2017 Last Verified: January 2009 Keywords provided by H. Lee Moffitt Cancer Center and Research Institute: Valproic Acid Epirubicin Solid Tumor Malignancies Additional relevant MeSH terms: Layout table for MeSH terms Neoplasms Cyclophosphamide Fluorouracil Epirubicin Valproic Acid Immunosuppressive Agents Immunologic Factors

2005 Clinical Trials

11926. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89. (Abstract)

. Patients with stage III disease treated with a novel six-drug combination showed improved survival compared with the Malignant Mesenchymal Tumor 84 study (MMT 84; 5-year OS, 60% v 42%, respectively). OS was not significantly better than that achieved in the previous MMT 84 study, but 49% of survivors were cured without significant local therapy.Selective avoidance of local therapy is justified in some patients, though further work is required to prospectively identify those for whom this is most (...) ) and event-free survival (EFS) were 71% and 57%, respectively. Primary site, T-stage, and pathologic subtype were independent factors in predicting OS by multivariate analysis. Differences between EFS and OS reflected local treatment strategy and successful re-treatment for some patients after relapse. Patients with genitourinary nonbladder prostate tumors had the most favorable outcome (5-year OS, 94%): the majority were boys with paratesticular tumors treated successfully without alkylating agents

2005 Journal of clinical oncology : official journal of the American Society of Clinical Oncology Controlled trial quality: uncertain

11927. Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)

Update Posted : January 24, 2013 Sponsor: National Cancer Institute (NCI) Information provided by (Responsible Party): National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: Randomized phase II trial to determine the effectiveness of vaccine therapy in treating patients who have advanced adenocarcinoma of the prostate (prostate cancer). Vaccines made from a person's prostate cancer cells may make the body build an immune response to kill tumor cells Condition or disease (...) Intervention/treatment Phase Adenocarcinoma of the Prostate Recurrent Prostate Cancer Stage IV Prostate Cancer Biological: recombinant fowlpox-prostate specific antigen vaccine Biological: recombinant vaccinia prostate-specific antigen vaccine Other: laboratory biomarker analysis Phase 2 Detailed Description: OBJECTIVES: I. Determine the toxicity and maximum tolerated dose of recombinant fowlpox prostate-specific antigen (PSA) vaccine in patients with advanced adenocarcinoma of the prostate. II. Determine

2000 Clinical Trials

11928. A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. (Abstract)

A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. The Southeastern Cancer Study Group has evaluated 5-fluorouracil administered intravenously weekly at a dosage of 600 mg. per M.2 as a single agent, and the 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil in patients with metastatic carcinoma of the bladder and of the prostate (...) and objective stability by National Prostatic Cancer Project criteria in 14 of 29 patients. Cyclophosphamide, doxorubicin and 5-fluorouracil induced an objective response in 7 of 22 patients and objective stability in 20 of 29. Thus, 5-fluorouracil administered in an adequate weekly dosage is established as an effective single agent in some patients with stage D carcinoma of the bladder or prostate. However, there is no significant added benefit as measured by survival obtained for these patients

1981 The Journal of urology Controlled trial quality: uncertain

11929. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. (Abstract)

Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer cells. Recently, PSMA has been found in the neovasculature in association with other solid malignant tumors, including clear cell renal carcinoma (RCC). We studied the expression of PSMA in different primary renal tumors.A tissue microarray was constructed from 60 normal kidney, 21 clear cell RCC (CCRCC), 20 (...) kidney and in the tumor-associated vasculature in the renal tumors. Positive PSMA staining was detected in 76.2% of CCRCC, 31.2% of chromophobe RCC, 52.6% of oncocytoma, 21.4% of transitional cell carcinoma, and 0% of PRCC and AML specimens. Its expression was greater in CCRCC than PRCC, chromophobe RCC, transitional cell carcinoma, and AML (P <0.001), but was not significantly different from the expression in oncocytoma (P = 0.79). PSMA expression did not correlate with the pathologic stage

2007 Urology

11930. Progression and survival in prostatic adenocarcinoma: a comparison of clinical stage, Gleason grade, S-phase fraction and DNA ploidy. Full Text available with Trip Pro

Progression and survival in prostatic adenocarcinoma: a comparison of clinical stage, Gleason grade, S-phase fraction and DNA ploidy. Clinical data were reviewed in 325 patients with prostatic adenocarcinoma followed up for a mean of 13 years. Paraffin-embedded tumour biopsy specimens from the primary tumours were available for flow cytometry (FCM) in 273 cases. Intra-tumour heterogeneity in DNA index (DI) was found in 4% of the tumours (54 cases were analysed). S-phase fraction (SPF) and DNA (...) prognostic value in all M0 tumours (P < 0.001). The results suggest that FCM can be used as an adjunct to conventional histological assessments for determination of the correct prognostic category in prostatic adenocarcinoma.

1994 British journal of cancer

11931. PROSPECTIVE EVALUATION OF MEN WITH STAGE T1C ADENOCARCINOMA OF THE PROSTATE Full Text available with Trip Pro

PROSPECTIVE EVALUATION OF MEN WITH STAGE T1C ADENOCARCINOMA OF THE PROSTATE The pathological characteristics of stage T1c cancers in the era of widespread prostate specific antigen (PSA) testing were determined, and the ability of pretreatment parameters to predict tumor significance in men with stage T1c disease was evaluated.Of 336 men with stage T1c prostate cancer seen between 1994 and 1996, 240 (71.4%) were treated with radical prostatectomy, 20 (6%) with radiation therapy and 76 (22.6 (...) (confined tumor 0.2 to less than 0.5 cm.3 with a Gleason score of less than 7), moderate (0.5 cm.3 or larger disease, or capsular penetration with a Gleason score of less than 7) and advanced (capsular penetration with a Gleason score of 7 or more, or positive margins, seminal vesicles or lymph nodes). Pathological characteristics of tumors in this series were compared to a previous series of 157 men with stage T1c cancers who underwent radical prostatectomy between 1988 and 1992.Of 240 men who

1997 The Journal of urology

11932. Urology—Important Advances in Clinical Medicine: Computerized Tomography, Lymphangiography and Gleason Scores for Staging Prostatic Adenocarcinoma Full Text available with Trip Pro

Urology—Important Advances in Clinical Medicine: Computerized Tomography, Lymphangiography and Gleason Scores for Staging Prostatic Adenocarcinoma 18749344 2010 06 30 2018 11 13 0093-0415 138 4 1983 Apr The Western journal of medicine West. J. Med. Urology-important advances in clinical medicine: computerized tomography, lymphangiography and Gleason scores for staging prostatic adenocarcinoma. 555-6 Torrey R R RR Janseen M M Ching V V eng Journal Article United States West J Med 0410504 0093 (...) -0415 1983 4 1 0 0 1983 4 1 0 1 1983 4 1 0 0 ppublish 18749344 PMC1010750 Cancer Treat Rep. 1977 Mar-Apr;61(2):297-306 872133 J Urol. 1977 Aug;118(2):278-82 894806 J Urol. 1980 Aug;124(2):223-5 6995622 J Urol. 1981 Jul;126(1):63-4 7253082 J Urol. 1980 Aug;124(2):226-31 7401236

1983 Western Journal of Medicine

11933. Comparison of leuprolide and diethylstilbestrol for stage D2 adenocarcinoma of prostate. (Abstract)

Comparison of leuprolide and diethylstilbestrol for stage D2 adenocarcinoma of prostate. In a controlled, prospective, randomized clinical trial, we evaluated the safety and efficacy of leuprolide, a superactive analog of luteinizing hormone releasing hormone, given in a single subcutaneous injection dose of 1 mg per day, versus diethylstilbestrol (DES) 3 mg per day by mouth in patients with previously untreated Stage D2 prostatic adenocarcinoma. Eleven leuprolide patients and 10 DES patients (...) . In addition, patients not responding to leuprolide generally experienced no benefit with crossover to DES, and vice versa. Serious adverse reactions were more common in the DES group and included fatal myocardial infarction, arrhythmia, deep venous thrombosis, and gynecomastia. Vasomotor flushing, disease flare, and injection site irritation occurred most often in leuprolide patients, but did not require modification or discontinuation of treatment.

1985 Urology Controlled trial quality: uncertain

11934. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study. (Abstract)

Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study. Seventy-eight patients with clinical Stage C adenocarcinoma of the prostate were prospectively randomized to receive either radiation alone or radiation and adjuvant estrogen (diethylstilbestrol). No patient had received any prior definitive treatment for cancer. Forty patients were randomized to receive radiotherapy only and 38 patients to receive (...) radiotherapy and estrogen. The median follow-up for all surviving patients was 14.5 years. Whether analyzed according to the original randomization or according to the treatment actually received, disease-free survival in the adjuvant estrogen group was strikingly and significantly higher than in the radiation-only group. At 5, 10, and 15 years patients receiving adjuvant estrogen had respective disease-free survival rates of 71%, 63%, and 63% compared with 49%, 43%, and 35% in patients having radiation

1988 International journal of radiation oncology, biology, physics Controlled trial quality: uncertain

11935. A Safety and Feasibility Study of Active Immunotherapy in Patients With Metastatic Prostate Carcinoma Using Autologous Dendritic Cells Pulsed With Antigen Encoded in Amplified Autologous Tumor RNA

by: National Center for Research Resources (NCRR) Study Details Study Description Go to Brief Summary: Purpose: This protocol proposes a safety and feasibility trial in patients with metastatic prostate cancer (stages D1-D3) investigating the induction of antitumor immunity by administration of cultured autologous peripheral blood precursor derived dendritic cells (DC), transfected with mRNA amplified from autologous prostate tumor tissue. The feasibility and dose-limiting toxicity of administering (...) specific immunity in vitro. Therefore, we hypothesize that administration of PSA RNA transfected DC will lead to detectable levels of PSA specific CTL in the peripheral blood of patients with PSA expressing metastatic prostate cancer. It is hoped that these T cell responses also have clinical antitumor activity. Condition or disease Intervention/treatment Phase Prostate Cancer Biological: Autologous dendritic cells transfected with amplified tumor RNA Phase 1 Detailed Description: Methods: Patients

2000 Clinical Trials

11936. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion. (Abstract)

on transrectal biopsy and treated with radical prostatectomy at one institution between 1986 and 1999 to determine the relation between putative pretreatment prognostic factors and disease-free survival. Clinical stage, Gleason score, perineural invasion, number of biopsies containing tumor, and serum prostate specific antigen (PSA) were evaluated as predictors of extracapsular extension, seminal vesicle involvement, lymph node metastases, and surgical margin involvement as well as outcome after surgery (...) Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion. Predicting outcome for men with clinically localized prostate carcinoma treated with curative intent remains imprecise and further evaluation of accepted and potential predictive factors is needed.The authors studied 696 men with localized prostate carcinoma diagnosed

2003 Cancer

11937. Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Full Text available with Trip Pro

Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. The transcription factor nuclear factor-kappaB (NF-kappaB) promotes the production of angiogenic, antiapoptotic, and prometastatic factors that are involved in carcinogenesis.Electromobility gel shift assays were used to evaluate NF-kappaB DNA binding in vitro. The functional relevance of NF-kappaB DNA binding was assessed (...) statistically different. There was no correlation with tumor grade or stage.NF-kappaB is constitutively activated in prostate cancer and functionally relevant in vitro. Immunohistochemistry of human prostatectomy specimens demonstrated overexpression of the active subunit of NF-kappaB, p65, and that this occurs at an early stage in the genesis of prostate cancer. This work supports the rationale for targeting NF-kappaB for the prevention and/or treatment of prostate cancer.

2004 Clinical Cancer Research

11938. Lymph node metastases of prostatic adenocarcinoma in the mesorectum in patients with adenocarcinoma or villous tumor of the rectum with collision phenomenon in a single lymph node: report of five cases. (Abstract)

Lymph node metastases of prostatic adenocarcinoma in the mesorectum in patients with adenocarcinoma or villous tumor of the rectum with collision phenomenon in a single lymph node: report of five cases. Lymph node involvement is the most important prognostic factor when staging patients with rectal cancer. Cancer originating from sites other than rectum rarely may metastasize to the mesorectum. We report five patients with metastatic prostatic carcinoma to mesorectal lymph nodes (...) percent formalin. All lymph nodes identified (range, 15-32; mean, 21 nodes per patient) were examined histologically.Of 106 lymph nodes examined, 20 contained metastases: 9 from rectal adenocarcinoma, 10 from prostatic adenocarcinoma, and 1 with metastatic foci from both tumors. The diagnosis of prostatic carcinoma was readily confirmed by immunostaining for prostatic-specific antigen, and prostatic acid phosphatase.Mesorectal lymph node dissection provides prognostic information in rectal cancer

2005 Diseases of the Colon & Rectum

11939. 2-Methoxyestradiol inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate: role of tumor necrosis factor-alpha-stimulated gene 6. Full Text available with Trip Pro

2-Methoxyestradiol inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate: role of tumor necrosis factor-alpha-stimulated gene 6. 2-Methoxyestradiol, an estrogenic metabolite, is in clinical trials for the treatment of hormone-refractory prostate cancer. However, neither the chemopreventive role nor the mechanism of 2-methoxyestradiol-induced biological activities is fully understood.Eight- and 24-week-old transgenic adenocarcinoma of mouse prostate (TRAMP) mice were (...) tissue array containing different grades of prostate tumors.Dietary administration of 2-methoxyestradiol prevented the development of preneoplastic lesions independent of progression stage. TSG-6 was low or undetectable in prostate cancer cells (LNCaP, PC-3, and DU145) and TRAMP tumors but up-regulated in response to 2-methoxyestradiol. Immunohistochemistry of the human prostate tumor array showed a decrease in TSG-6-positive cells with increasing grade relative to normal prostate (P = 0.0001

2006 Clinical Cancer Research

11940. Transrectal Ultrasound of Prostatic Carcinoma: A new way to evaluate benign and malignant conditions Full Text available with Trip Pro

Transrectal Ultrasound of Prostatic Carcinoma: A new way to evaluate benign and malignant conditions The purpose of this paper is to review the indications for transrectal ultrasound; to briefly describe the sonographic technique; to describe the sonographic findings of prostatic carcinoma; to review the indications for transrectal sonographic-guided biopsy; and to discuss the controversles of routine screening and staging.

1991 Canadian Family Physician

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>